3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
18
NIH
16
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
12
Thoracic
8
Plasma cell
7
Dermatologic
5
Tumor-Agnostic
3
Gastrointestinal
2
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
CNS
1
Breast
1
Conditions
Neuroectodermal Tumors
1
Neuroblastoma
1
Neoplasms
1
Interventions
Temozolomide
123
Radiotherapy
47
Bevacizumab
46
Lomustine
25
Radiation
20
Nivolumab
17
Irinotecan
16
Carboplatin
16
Cyclophosphamide
14
Granulocyte-Macrophage Colony-Stimulating Factor
13
pembrolizumab
11
dabrafenib
10
Trastuzumab
10
Surgical Procedures, Operative
10
Capecitabine
10
paclitaxel-Angiopep-2 conjugate
8
TIC10 compound
8
Paclitaxel
8
Gemcitabine
8
Carmustine
8
trametinib
7
Topotecan
7
IL13-PE38
7
Everolimus
7
Drug Therapy
7
Aminolevulinic Acid
7
AZD 6244
7
3-Iodobenzylguanidine
7
fludarabine
6
enzastaurin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Vorinostat
×
CNS
×
Clear all
NCT03561259
2023-02-16
OPTIMUM
Jubilant DraxImage Inc.
Phase 2
Unknown
60 enrolled